C-reactive protein and glycemic control in adults with diabetes.

OBJECTIVE Recent evidence suggests that poor glycemic control is significantly associated with the development of macrovascular complications of diabetes. Studies have indicated that C-reactive protein (CRP) is an important risk factor for cardiovascular disease. The purpose of this study was to determine the relation between CRP and HbA(1c) in a large national sample of individuals with diabetes. RESEARCH DESIGN AND METHODS A nationally representative sample of noninstitutionalized U.S. adults aged 17 years and over with nongestational diabetes was derived from the National Health and Nutrition Examination Survey III (1988-1994) (n = 1,018). Respondents with diabetes were stratified by HbA(1c) level. The main outcome measure was elevated (>0.30 mg/dl) CRP. RESULTS In unadjusted analyses, respondents with diabetes who had elevated HbA(1c) levels (> or =9.0%) had a significantly higher percent of elevated CRP than people with low (<7%) HbA(1c) levels (P < 0.001). In adjusted regression analysis, after controlling for age, race, sex, smoking, length of time with diabetes, insulin, and BMI, HbA(1c) was significantly associated with an increased likelihood of elevated CRP for HbA(1c) >9.0% (OR 2.15, 95% CI 1.07-4.32) and for HbA(1c) >11.0% (4.40, 1.87-10.38). Higher HbA(1c) also predicted elevated CRP in the regression model when HbA(1c) was analyzed as a continuous variable (1.20, 1.07-1.34). CONCLUSIONS In this study, the likelihood of elevated CRP concentrations increased with increasing HbA(1c) levels. These findings suggest an association between glycemic control and systemic inflammation in people with established diabetes.

[1]  N. Danchin,et al.  C-Reactive protein and coronary artery disease: additional evidence of the implication of an inflammatory process in acute coronary syndromes. , 1999, American heart journal.

[2]  A. Aljada,et al.  A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis. , 2002, The American journal of cardiology.

[3]  M. Pfeffer,et al.  Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein , 1999 .

[4]  Gerardo Heiss,et al.  Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study , 1999, The Lancet.

[5]  S. Haffner,et al.  Effects of Diabetes and Level of Glycemia on All-Cause and Cardiovascular Mortality: The San Antonio Heart Study , 1998, Diabetes Care.

[6]  H. Becher,et al.  The association of leukocyte count, fibrinogen and C-reactive protein with vascular risk factors and ischemic vascular diseases. , 1996, Thrombosis research.

[7]  H. Brenner,et al.  Association between C-reactive protein and features of the metabolic syndrome: a population-based study. , 2000, Diabetes care.

[8]  L. Kuller,et al.  Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[9]  M. Rodríguez-Moran,et al.  Increased levels of C-reactive protein in noncontrolled type II diabetic subjects. , 1999, Journal of diabetes and its complications.

[10]  A. Aljada,et al.  Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes. , 2000, The Journal of clinical endocrinology and metabolism.

[11]  L. Kuller,et al.  The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. , 2001, Diabetes.

[12]  S. Mudaliar,et al.  Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. , 2002, Diabetes care.

[13]  S. Haffner,et al.  Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). , 2000, Circulation.

[14]  E. Ford.  Body mass index, diabetes, and C-reactive protein among U.S. adults. , 1999, Diabetes care.

[15]  R. Holman,et al.  Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23) , 1998, BMJ.

[16]  S. Fichtlscherer,et al.  Elevated C-Reactive Protein Levels and Impaired Endothelial Vasoreactivity in Patients With Coronary Artery Disease , 2000, Circulation.

[17]  R J Glynn,et al.  C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. , 1998, Circulation.

[18]  S. Haffner,et al.  Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. , 2002, Diabetes.

[19]  Z. Bloomgarden,et al.  Diabetes complications. , 2004, Diabetes care.

[20]  M H Wener,et al.  The influence of age, sex, and race on the upper reference limit of serum C-reactive protein concentration. , 2000, The Journal of rheumatology.

[21]  M. Trevisan,et al.  Associations of serum C-reactive protein with fasting insulin, glucose, and glycosylated hemoglobin: the Third National Health and Nutrition Examination Survey, 1988-1994. , 2002, American journal of epidemiology.

[22]  J. Manson,et al.  C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. , 2001, JAMA.

[23]  P. Ridker,et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[24]  Rapid Reduction in C-Reactive Protein With Cerivastatin Among 785 Patients With Primary Hypercholesterolemia , 2001 .

[25]  N Rifai,et al.  Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. , 2001, JAMA.

[26]  S. Coppack,et al.  C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[27]  R. Goldberg.  Cardiovascular disease in diabetic patients. , 2000, The Medical clinics of North America.

[28]  A. Aljada,et al.  Inhibitory effect of a two day fast on reactive oxygen species (ROS) generation by leucocytes and plasma ortho-tyrosine and meta-tyrosine concentrations. , 2001, The Journal of clinical endocrinology and metabolism.

[29]  L. Tenkanen,et al.  Joint effects of C-reactive protein and other risk factors on acute coronary events. , 2001, American heart journal.

[30]  武井泉,et al.  United Kingdom Prospective Diabetes Study (UKPDS) , 1999 .

[31]  P. Ridker,et al.  Rapid Reduction in C-Reactive Protein With Cerivastatin Among 785 Patients With Primary Hypercholesterolemia , 2001, Circulation.

[32]  Ose,et al.  Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events* , 2002 .

[33]  E. Gunter,et al.  Laboratory procedures used for the third National Health and Nutrition Examination Survey (NHANES III), 1988-1994 , 1996 .

[34]  A. Aljada,et al.  Both lipid and protein intakes stimulate increased generation of reactive oxygen species by polymorphonuclear leukocytes and mononuclear cells. , 2002, The American journal of clinical nutrition.